| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Rosuvastatin | Green: Administer standard doses | Administer standard doses | Potential for increased rosuvastatin adverse effects (e.g. myalgias, increased transaminases) |
Not reported |
5 mg orally x 1 | AUC increased 31%; Cmax increased 57% |
|
| Darunavir Rosuvastatin 888 | Yellow: Adjust dosing | Adjust dosing to avoid increased levels of rosuvastatin | Increased risk of rosuvastatin adverse effects (e.g. myopathy, rhabdomyolysis); No change in lipid lowering ability within 35 day study period |
No significant change |
10 mg once daily | Cmax increase 144%,AUC increase 48% |
Consider using alternative agents. If coadministering, consider initiating low dose rosuvastatin 5 mg daily |
| Atazanavir Rosuvastatin 769 | Yellow: Adjust dosing | Adjust dosing to avoid increased levels of rosuvastatin | Potential for increased rosuvastatin adverse effects (e.g. myopathy) |
10 mg daily | Rosuvastatin AUC increased 213%, Cmax increased 600% |
Initiate lowest dose and titrate carefully. Do not exceed 10mg rosuvastatin daily. |
|
| Elvitegravir Rosuvastatin 128 | Yellow: Adjust dosing | Adjust dosing to avoid increased levels of rosuvastatin | Potential for increased risk of rosuvastatin adverse effects (e.g. myopathy) |
No significant change |
10 mg single dose | Cmax increased 89%, AUC increased 38%, Cmin increased 43% |
Initiate rosuvastatin at lowest dose and titrate carefully. Monitor for adverse effects. |
| Fostemsavir Rosuvastatin 3 | Yellow: Adjust dosing | Adjust dosing to avoid increased levels of rosuvastatin | Increased statin exposure and risk of statin associated adverse events |
Not studied |
10 mg single dose | Cmax increased 78%, AUC increased 69% |
If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events |
